Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.
Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.
Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.
For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) reported its financial results for Q3 2020, with revenues of $2.3 million, a decrease from $3.3 million in Q3 2019. Operating expenses surged to $23.3 million, primarily due to increased spending on clinical trials for ARCT-021 and ARCT-810, leading to a net loss of $21.0 million, or $0.92 per share. Despite the losses, the company’s cash position improved to $307.1 million, bolstered by equity offerings. The ARCT-021 COVID-19 vaccine candidate shows promising preliminary results, and the ARCT-810 candidate for OTC deficiency is advancing into further studies.
Arcturus Therapeutics (Nasdaq: ARCT) reported positive interim results from its Phase 1/2 study of ARCT-021, a COVID-19 vaccine candidate. Conducted in Singapore, the trial enrolled 106 subjects, revealing robust anti-spike protein IgG immune responses across multiple doses. The vaccine was well tolerated, showing a favorable safety profile. Additionally, Arcturus secured a financial commitment of up to $220 million from Singapore's Economic Development Board (EDB) to support vaccine manufacturing, including a $45 million loan linked to future sales.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced its participation in several upcoming investor and scientific conferences. The company will present at the International mRNA Health Conference on November 10, 2020, at 1:40 p.m. ET, and at the Stifel Healthcare Conference on November 17, 2020, at 3:20 p.m. ET. Additionally, Arcturus will engage in a fireside chat at the Piper Sandler Healthcare Conference on November 23, 2020, at 10:00 a.m. ET. The company focuses on mRNA medicines and vaccines for infectious diseases and rare diseases.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the quarter and nine months ended September 30, 2020, after market close on November 9, 2020. A conference call and webcast will be held at 4:30 PM ET on the same day to discuss the results and provide a corporate overview. The company specializes in mRNA medicines, focusing on vaccines for infectious diseases and rare diseases of the liver and respiratory system. Founded in 2013, Arcturus has developed a pipeline that includes self-replicating mRNA vaccine candidates for COVID-19 and influenza.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has completed the first three dose escalation cohorts in its Phase 1 study of ARCT-810, an mRNA-based therapeutic for Ornithine Transcarbamylase (OTC) deficiency. The trial is randomized, double-blind, and placebo-controlled, evaluating safety, tolerability, and pharmacokinetics. Preliminary results show good tolerability and a favorable pharmacokinetic profile. The fourth cohort is expected to complete this quarter, with final results to be reported soon. The company plans to initiate a second clinical study in patients with OTC deficiency this quarter.
Arcturus Therapeutics Holdings announced preclinical results for its vaccine LUNAR®-COV19 (ARCT-021), showing a strong antibody response and 100% protection against SARS-CoV-2 following a single dose vaccination in mice. The study indicates robust neutralizing antibody titers persisting up to day 60, along with significant T cell responses. The clinical study is on track with results expected in Q4 2020. Collaboration with Duke-NUS Medical School enhances credibility, and the company emphasizes the potential of its low-dose, single-shot vaccine approach for COVID-19 mass vaccination.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the successful dosing of all subjects in the first cohort of its Phase 1/2 clinical study for ARCT-021, a self-replicating mRNA vaccine for COVID-19. The study aims to evaluate safety and immunogenicity in younger adults, with clinical data expected in Q4 2020. Preclinical results demonstrated 100% seroconversion after a single low-dose administration, indicating promising efficacy. The vaccine is designed for low-dose, single administration, potentially facilitating mass vaccination efforts against COVID-19.
Arcturus Therapeutics Holdings announced progress in its clinical pipeline, with the initiation of Phase 1/2 studies for its COVID-19 mRNA vaccine candidate, ARCT-021, in collaboration with Duke-NUS Medical School. Dosing of subjects is expected imminently, with initial data anticipated by Q4 2020. Additionally, the Phase 1 study for ARCT-810, targeting ornithine transcarbamylase deficiency, continues. The company successfully raised $280 million in 2020 through equity offerings, enhancing its financial position, boasting a cash balance of $136.1 million as of June 30, 2020.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the appointment of Lance Kurata as Chief Legal Officer, effective August 10, 2020. Formerly a partner at Mintz, Kurata brings extensive expertise in biotechnology law, focusing on transactions and intellectual property, which is critical as Arcturus advances its mRNA therapeutic platform. The company anticipates significant clinical trial data this year for its COVID-19 vaccine candidate ARCT-021 and the investigational therapy ARCT-810 for Ornithine Transcarbamylase deficiency.
Arcturus Therapeutics Holdings Inc. announced the closing of its public offering of 3,753,773 shares at $53.00 each, after the underwriters fully exercised their option for an additional 489,622 shares. The offering generated approximately $200 million in gross proceeds. The funds are designated for the development of the LUNAR-COV19 vaccine, along with advancing other therapeutic programs, early research, and corporate purposes. The offering was made under a shelf registration statement effective since May 2020, with Citigroup, Guggenheim Securities, and Barclays as joint managers.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
